Get started

Financials · TELA

TELA Bio Inc. (TELA) financials

For the twelve months ended Jun 30, 2026, TELA Bio Inc. reported $79.91M of revenue and -$41.18M of net income.

Revenue, TTM
$79.91M
Revenue growth, YoY
+6.1%
Net income, TTM
-$41.18M
Net margin
-51.5%
Free cash flow, TTM
-$31.62M
EPS, diluted, TTM
-$0.77
Cash
$30.42M
Total debt
$56.08M
P/S
0.45
Market cap
$36.3M
Annual revenue$80.28M
FY2017FY2025
Annual net income-$38.83M
FY2017FY2025
Annual free cash flow-$28.67M
FY2017FY2025

TELA revenue and earnings growth

TELA revenueQ2 2026$19.29M

Quarter YoY
-4.5%
QoQ
+1.2%
FY YoY
+15.8%
5Y CAGR
+34.5%

TELA revenue was $19.29M in fiscal Q2 2026 (ended Jun 30, 2026), down 4.5% from a year earlier and up 1.2% from the prior quarter. For the full fiscal 2025 it was $80.28M, up 15.8% from fiscal 2024. Compound annual growth was +34.5% over 5 years. It rose in each of the last 8 fiscal years. Fiscal 2025 is the highest of the 9 fiscal years on file.

TELA net incomeQ2 2026-$11.26M

TELA net income was -$11.26M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.92M a year earlier. For the full fiscal 2025 it was -$38.83M, compared with -$37.84M in fiscal 2024.

TELA EPSQ2 2026-$0.20

TELA diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.22 a year earlier. For the full fiscal 2025 it was -$0.83.

TELA free cash flowQ2 2026-$9.44M

TELA free cash flow was -$9.44M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.02M a year earlier. For the full fiscal 2025 it was -$28.67M, compared with -$42.58M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$80.28M$69.30M$58.45M$41.42M$29.46M$18.21M$15.45M$8.27M$4.25M
Gross profit$54.34M$46.49M$40.11M$27.04M$18.81M$11.23M$9.27M$2.94M$2.53M
Research and development$9.22M$8.81M$9.62M$8.94M$6.74M$4.25M$4.15M$4.34M$5.79M
Selling, general and admin$15.69M$14.72M$14.89M$13.86M$12.46M$10.14M$6.22M$4.90M$4.96M
Operating income-$33.76M-$34.12M-$44.08M-$39.01M-$29.45M-$25.27M-$19.16M-$17.78M-$16.92M
Interest expense$5.25M$5.29M$5.22M$4.05M$3.60M$3.56M$3.61M$1.80M$4.56M
Pre-tax income-$38.60M-$37.98M-$46.66M-$44.30M-----
Income tax$230.0K-$144.0K-------
Net income-$38.83M-$37.84M-$46.66M-$44.30M-$33.28M-$28.79M-$22.43M-$21.09M-$21.33M
EPS, basic-$0.83-$1.33-$2.04-$2.72-$2.30-$2.23-$17.10-$101.41-
EPS, diluted-$0.83-$1.33-$2.04-$2.72-$2.30-$2.23-$17.10-$101.41-
Diluted shares46.9M28.5M22.9M16.3M14.5M12.9M1.8M294,988291,963

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$50.84M$52.94M$46.99M$42.02M$43.93M$74.39M$45.30M$17.28M$11.35M
Short-term investments-----$0$9.29M--
Receivables$10.35M$10.10M$9.74M$6.62M$4.23M$2.68M$2.84M$1.30M-
Inventory$11.02M$12.78M$13.16M$11.79M$7.66M$3.91M$4.60M$4.35M-
Current assets$75.58M$78.07M$71.73M$62.45M$59.05M$83.22M$64.33M$23.25M-
Total assets$81.42M$86.57M$78.05M$67.86M$62.54M$86.46M$67.92M$27.23M-
Current liabilities$17.98M$15.60M$16.97M$12.40M$10.57M$6.61M$6.71M$9.56M-
Long-term debt$55.65M$41.12M$40.52M$39.92M-----
Total debt$55.65M$41.12M$40.52M$39.92M$31.49M$30.83M$30.24M--
Total liabilities$75.11M$58.11M$59.17M$53.55M$42.45M$37.43M$36.96M$40.94M-
Shareholders' equity$6.31M$28.46M$18.88M$14.30M$20.10M$49.03M$30.96M-$137.86M-$108.17M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$28.22M-$41.59M-$40.86M-$40.75M-$30.43M-$24.46M-$25.52M-$19.92M-$16.37M
Capital expenditures$448.0K$989.0K$611.0K$872.0K$627.0K$167.0K$197.0K$62.0K$114.0K
Free cash flow-$28.67M-$42.58M-$41.47M-$41.62M-$31.06M-$24.62M-$25.72M-$19.99M-$16.48M
Investing cash flow$846.0K$4.45M-$599.0K-$1.87M-$627.0K$9.12M-$11.98M-$1.56M-$101.0K
Financing cash flow$25.75M$43.06M$46.27M$40.85M$585.0K$44.41M$65.53M$27.41M$26.34M
Stock-based compensation$3.80M$4.36M$5.03M$3.99M$3.66M$2.06M$457.0K$216.0K$197.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY15.8%18.6%41.1%40.6%61.8%17.9%86.7%94.9%-
Gross margin67.7%67.1%68.6%65.3%63.9%61.7%60.0%35.6%59.6%
Operating margin-42.0%-49.2%-75.4%-94.2%-100.0%-138.8%-124.1%-214.9%-398.7%
Net margin-48.4%-54.6%-79.8%-106.9%-112.9%-158.1%-145.2%-254.9%-502.6%
Free cash flow margin-35.7%-61.4%-70.9%-100.5%-105.4%-135.2%-166.5%-241.6%-388.3%
Return on equity-615.1%-133.0%-247.1%-309.7%-165.6%-58.7%-72.4%--
Return on assets-47.7%-43.7%-59.8%-65.3%-53.2%-33.3%-33.0%-77.5%-
Current ratio4.205.014.235.035.5812.609.582.43-
Debt to equity8.821.452.152.791.570.630.98--

Source: XBRL data TELA Bio Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TELA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TELA$79.91M+6.1%-$41.18M-51.5%$36.3M
SYK$26.30B+7.9%$3.62B13.8%$123.45B
MMM$25.25B+1.7%$3.54B14.0%$97.85B
BSX$21.07B+8.9%$3.50B16.6%$64.78B
BDX$23.25B+17.4%$941.00M4.0%$57.91B
MDLN$30.68B-$683.00M2.2%$53.81B
RMD$5.73B+9.0%$1.59B27.8%$32.93B
DXCM$5.10B+13.0%$991.00M19.4%$29.81B
WST$3.40B+12.6%$638.90M18.8%$28.74B

TELA FAQ

9 questions
  • What is TELA revenue?
    TELA Bio Inc. (TELA) reported $79.91M of revenue for the twelve months ended Jun 30, 2026. That is up 6.1% from the year before. Revenue for fiscal 2025 was $80.28M.
  • Is TELA profitable?
    No. TELA Bio Inc. reported a net loss of $41.18M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does TELA have?
    TELA Bio Inc. reported $30.42M in cash and cash equivalents and $56.08M of debt on its most recent balance sheet in SEC filings.
  • How fast is TELA revenue growing?
    TELA Bio Inc.'s revenue changed +15.8% in fiscal 2025, to $80.28M. Its compound annual growth rate was +34.5% over 5 years.
  • What is TELA gross margin?
    TELA Bio Inc.'s gross profit was $54.19M on $79.91M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 67.8%.
  • What is TELA free cash flow?
    TELA Bio Inc. generated -$31.62M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$31.14M less capital expenditures.
  • What is TELA earnings per share?
    Diluted earnings per share were -$0.77 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did TELA last report financial results?
    The latest statements here come from TELA Bio Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this TELA financial data come from?
    Quantisnow builds these statements from the structured XBRL data TELA Bio Inc. files with the SEC. It is provided for information only and is not investment advice.